Fidaxomicin: Additional Phase III data

Pooled data from a pair of double-blind Phase III trials in 1,164 patients showed that in patients with a recurrent episode of CDI within 3

Read the full 253 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE